Valerio Therapeutics (XPAR:ALVIO) Cash Flow for Dividends: €0.00 Mil (TTM As of Dec. 2025)


XPAR:ALVIO Valerio Therapeutics XPAR:ALVIO
28 GF Score
Price €0.51
GF Value €0.07
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Valerio Therapeutics Cash Flow for Dividends?

Valerio Therapeutics XPAR:ALVIO +37.84% 28 Cash Flow for Dividends is €0.00 Mil as of Dec. 2025. GuruFocus rates XPAR:ALVIO with a GF Score™ of 28/100 and a GF Value™ of €0.07 (Significantly Overvalued). The stock has 9 warning signs investors should review.

Valerio Therapeutics's cash flow for dividends for the six months ended in Dec. 2025 was €0.00 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Dec. 2025 was €0.00 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

Valerio Therapeutics Cash Flow for Dividends Related Terms

Valerio Therapeutics Cash Flow for Dividends Historical Data

* Premium members only.

The historical data trend for Valerio Therapeutics's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Valerio Therapeutics Cash Flow for Dividends Chart

Valerio Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Flow for Dividends
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Valerio Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Cash Flow for Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XPAR:ALVIO
28GF Score
Valerio Therapeutics XPAR:ALVIO
Cash Flow for Dividends is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Valerio Therapeutics Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow for Dividends of €0.00 Mil mean?
Valerio Therapeutics (XPAR:ALVIO) has a Cash Flow for Dividends of €0.00 Mil as of Dec. 2025. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Valerio Therapeutics and its competitors.
Is Valerio Therapeutics' Cash Flow for Dividends too high?
Valerio Therapeutics' current Cash Flow for Dividends is €0.00 Mil. Overall, Valerio Therapeutics has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Valerio Therapeutics' Cash Flow for Dividends compare to VRTX and REGN?
Valerio Therapeutics' Cash Flow for Dividends of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow for Dividends for a Biotechnology company?
A good Cash Flow for Dividends depends on the Biotechnology industry context. However, Cash Flow for Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow for Dividends mean?
A high Cash Flow for Dividends can signal that a stock is expensive relative to its fundamentals. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Valerio Therapeutics and its competitors. Valerio Therapeutics's current Cash Flow for Dividends is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valerio Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Valerio Therapeutics (XPAR:ALVIO) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.07, compared to a current price of €0.51 — trading 628.6% above its estimated fair value. The current Cash Flow for Dividends is €0.00 Mil. Valerio Therapeutics' overall GF Score™ is 28/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow for Dividends calculated?
Cash Flow for Dividends is calculated from a company's financial statements. For Valerio Therapeutics (XPAR:ALVIO), the current Cash Flow for Dividends is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Valerio Therapeutics (XPAR:ALVIO) Overvalued in 2026?

Based on GuruFocus' analysis, Valerio Therapeutics stock appears to be overvalued. The current stock price of €0.51 is trading 628.6% above its estimated GF Value™ of €0.07. GuruFocus considers Valerio Therapeutics to be Significantly Overvalued.

Key valuation signals for XPAR:ALVIO:

  • Cash Flow for Dividends: €0.00 Mil
  • GF Value™: €0.07 vs. price of €0.51 (628.6% above fair value)
  • GF Score™: 28/100 with 9 warning signs

No single metric tells the full story. See the XPAR:ALVIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Valerio Therapeutics Business Description

Other Exchanges 0NWK:UKC4X:Germany
Address 49, Boulevard du General, Martial Valin, Paris, FRA, 75015
Valerio Therapeutics is a clinical-stage biotechnology company developing drug candidates using three proprietary platforms: the PlatON platform, DecoyTAC, and the V-Body platform, generating single-domain therapeutic antibodies. The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners. Its pipeline includes Metabolic Diseases, Immunology & Inflammatory.
28GF Score

Get the complete analysis for XPAR:ALVIO

Cash Flow for Dividends is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.51
Price
€0.07
GF Value